IP Library Granted Patent US 9,597,386
Granted Patent B2
US 9,597,386 · App. 13/796,653 · Granted Mar 21, 2017

Outer membrane proteins of

Inventors: Brice Dean Lilly (St. Joseph, MO); Jeffrey P. Knittel (Parkville, MO)
Assignee: Boehringer Ingelheim Vetmedica, Inc.
A61K39/102C07K14/285G01N33/56911G01N33/6854A61K2039/552G01N2333/285
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,597,386
App. No.
13/796,653
Granted
Mar 21, 2017
Kind
B2
Abstract

The present invention relates to immunological compositions of outer membrane proteins (OMPs) of H. somni , as well as methods of extraction, a respiratory challenge model, methods of administration and diagnostic assays and kits.

Claims (9)

1. An immunogenic composition comprising at least one outer membrane protein (OMP) from Histophilus somni selected from the group consisting of PTA 12755, PTA 12756 and combinations thereof and a physiologically-acceptable vehicle, wherein the OMP is generated by incubating Histophilus somni bacteria, suspending Histophilus somni bacteria in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer containing protease inhibitors, lysing the Histophilus somni bacteria by cycles of freezing and thawing, and further Histophilus somni bacteria lysing by sonication cycles, resuspending in HEPES containing protease inhibitors, and then solubilizing non-protein components and then extracting solely by SDS extraction.

2. The immunogenic composition of claim 1 , wherein the physiologically-acceptable vehicle is selected from the group consisting of a pharmaceutically or veterinary acceptable carrier, adjuvant, or combination thereof.

3. A method of provoking an immune response against Histophilus somni infection comprising the administration of the immunogenic composition of claim 1 to a subject.

4. A method of reducing the incidence or severity of a clinical sign associated with Histophilus somni infection comprising the administration of the immunogenic composition of claim 1 to a subject in need thereof, wherein the reduction of the incidence of or the severity of a clinical sign is at least 10% relative to a subject not receiving the immunogenic composition.

5. The method of claim 4 , wherein the clinical sign is selected from the group consisting of labored or rapid respiration, coughing, anorexia, depression or lethargy, nasal and ocular discharge, and mortality.

6. The method of claim 4 , wherein the subject is an animal selected from the group consisting of a bovine or ovine.

7. A kit comprising at least one OMP Histophilus somni peptide according to claim 1 , an immunogenic carrier, a container for packaging the OMP Histophilus somni peptide and immunogenic carrier, a set of printed instructions; and a dispenser capable of administering a vaccine to an animal.

8. A kit for preparing the immunogenic composition of claim 1 , comprising (i) the OMP Histophilus somni peptide and (ii) the physiologically-acceptable vehicle, wherein (i) and (ii) are packaged separately.

9. The kit of claim 8 , further comprising a dispenser.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jul 24, 2020
From: BOEHRINGER INGELHEIM VETMEDICA, INC.; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 053310/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2013
From: LILLY, BRICE DEAN; KNITTEL, JEFFREY P.
To: BOEHRINGER INGELHEIM VETMEDICA, INC.
Reel/Frame 030061/0754 →
Continuity (2)
Provisional Application 61620652 · Apr 5, 2012
Related Publication 20130266613A1 · Oct 10, 2013